Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH5201 in Advanced Solid Tumors
NCT04261075Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of IPH5201 in solid tumor and pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by MedImmune. Primary endpoints: Incidence of adverse events up to 7 months, Incidence of clinically significant laboratory values up to 7 months and 1 more. Started Mar 2020; status: completed.
02
Drugs
IPH5201
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04261075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261075.